Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

2.

Catching the spirit: a study of Bureau of Land Management wild horse adopters in New England.

Koncel MA, Rutberg AT.

J Appl Anim Welf Sci. 2012;15(1):32-52. doi: 10.1080/10888705.2012.624052.

PMID:
22233214
3.

State-level approaches to managing the use of contraceptives in wildlife in the United States.

Eisemann JD, O'Hare JR, Fagerstone KA.

J Zoo Wildl Med. 2013 Dec;44(4 Suppl):S47-51.

PMID:
24437085
4.

COMPARISON OF CHEMICAL AND SURGICAL VASECTOMY ON TESTICULAR ACTIVITY IN FREE-ROAMING HORSES (EQUUS CABALLUS).

Scully CM, Lee RL, Pielstick L, Medlock J, Patton KM, Collins GH, Kutzler MA.

J Zoo Wildl Med. 2015 Dec;46(4):815-24. doi: 10.1638/2014-0227.1.

PMID:
26667538
5.

Immunocontraception in wild horses (Equus caballus) extends reproductive cycling beyond the normal breeding season.

Nuñez CM, Adelman JS, Rubenstein DI.

PLoS One. 2010 Oct 26;5(10):e13635. doi: 10.1371/journal.pone.0013635.

6.

Hoofbeats From the Currituck Outer Banks: A Study of the Corolla Wild Horse Fund Adoption Program.

Koncel MA.

J Appl Anim Welf Sci. 2016;19(1):37-48. doi: 10.1080/10888705.2015.1091738. Epub 2015 Oct 19.

PMID:
26480204
7.

Return on investment: a fuller assessment of the benefits and cost savings of the US publicly funded family planning program.

Frost JJ, Sonfield A, Zolna MR, Finer LB.

Milbank Q. 2014 Dec;92(4):696-749. doi: 10.1111/1468-0009.12080. Epub 2014 Oct 15.

8.

Medical care cost savings from adolescent contraceptive use.

Trussell J, Koenig J, Stewart F, Darroch JE.

Fam Plann Perspect. 1997 Nov-Dec;29(6):248-55, 295.

9.

Cost savings from the provision of specific methods of contraception in a publicly funded program.

Foster DG, Rostovtseva DP, Brindis CD, Biggs MA, Hulett D, Darney PD.

Am J Public Health. 2009 Mar;99(3):446-51. doi: 10.2105/AJPH.2007.129353. Epub 2008 Aug 13.

10.
11.
12.

Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis.

Sullivan PW, Follin SL, Nichol MB.

Pharmacoeconomics. 2004;22(14):929-42.

PMID:
15362929
13.

Farm-level economic analysis of the US National Johne's Disease Demonstration Herd Project.

Groenendaal H, Wolf CA.

J Am Vet Med Assoc. 2008 Dec 15;233(12):1852-8. doi: 10.2460/javma.233.12.1852.

PMID:
19072597
14.

Report on financing the new model of family medicine.

Spann SJ; Task Force 6 and the Executive Editorial Team.

Ann Fam Med. 2004 Dec 2;2 Suppl 3:S1-21.

15.

[Cost-benefit model of the Rwanda family planning program].

Rwanda. Office National de la Population ONAPO.

Imbonezamuryango. 1991 Aug;(21):25-37. French.

PMID:
12317097
16.

The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.

Armstrong GL, Billah K, Rein DB, Hicks KA, Wirth KE, Bell BP.

Pediatrics. 2007 Jan;119(1):e22-9.

PMID:
17200247
17.

Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.

Huse DM, Song X, Ozminkowski RJ, Maguire J, Williams SA, Borok GM, McDonough K.

Clin Ther. 2006 Sep;28(9):1425-42.

PMID:
17062315
18.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
20.

Retrospective cost-effectiveness analyses for polio vaccination in the United States.

Thompson KM, Tebbens RJ.

Risk Anal. 2006 Dec;26(6):1423-40.

PMID:
17184390
Items per page

Supplemental Content

Write to the Help Desk